Skip to search formSkip to main contentSkip to account menu

APD 356

Known as: APD-356, APD356 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lorcaserin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The design , synthesis and evaluation of tetra-substituted pyridines as potent 5-HT 2 C receptor agonists
A series of pyrido[3,4-d]azepines that are potent and selective 5-HT2C receptor agonists is disclosed. Compound 7 (PF-04781340… 
Review
2010
Review
2010
ACS chemical neuroscience molecule spotlight on Lorcaserin.
Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine(2C) (5-HT(2C)) receptor agonists. On… 
Review
2006
Review
2006
Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors
The serotonin, norepinephrine, dopamine, and endocannabinoid systems, as well as a host of other systems, mediate hunger and… 
Review
2005
Review
2005
APD-356 (Arena).
Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the… 
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials reported in current literature and congresses. The data… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)